Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT03918447 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03918447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03918447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
May 29, 2019
Completion date
August 8, 2023
Enrollment
667 (actual)
Sites
137

Conditions

As the registry lists them; a condition with its own page is linked.

adpkd, autosomal dominant polycystic kidney